Xelpmoc's Mihup ARR dropped from ₹1 billion to $1 million. No explanation given.
Management also walked back a specific breakeven timeline after giving one last quarter, raising credibility questions on both portfolio reporting and forward guidance.
What's new
- Q4 FY26 revenue ₹10.8 million, up 52% YoY but down 3.6% QoQ.
- Portfolio company Mihup's contracted ARR is now $1 million, down from a previously stated ₹1 billion.
- CFO Srinivas Koora refused to provide FY27 EBITDA breakeven timeline when directly asked.
Themes from the call
Portfolio Reporting
The stated ARR for Mihup fell 90%+ from the November 2025 figure without explanation, a major discrepancy in portfolio company metrics.
Guidance
Management withdrew a specific breakeven timeline it had previously offered, citing policy against disclosing future numbers.
Strategic Shift
Revenue is now 100% corporate segment; startup exposure is through portfolio investments, not operations.
Guidance watch
- Management previously guided breakeven within 1-2 quarters. This quarter they refused to provide any timeline, stating 'we will not be able to disclose any future numbers'.
Risk flags
- The Mihup ARR discrepancy is either a reporting error or an unexplained write-down, both damaging to credibility.
- Refusal to guide on breakeven reverses a prior commitment to transparency on timelines.
- The Q&A session was cut off mid-response to a direct analyst question about FY27 metrics.
Key quotes
-
"Mihup currently has contracted ARR of INR 1 billion."
— Xelpmoc management, Nov 2025 call -
"Mihup currently has a contracted ARR of 1 million USD."
— Xelpmoc management, Jun 2026 call -
"The first thing is we are looking at reaching out to a breakeven in the next 1, 2 quarters."
— Xelpmoc management, Nov 2025 call -
"We will not be able to disclose any future numbers."
— CFO Srinivas Koora, Jun 2026 call
The brief
Xelpmoc's quarterly call contained two striking reversals. The first concerns Mihup, a conversational AI portfolio company. In November 2025, management told investors Mihup had a contracted ARR of ₹1 billion. This quarter, the figure was $1 million. That's a 90%+ drop, with no explanation. The second is a guidance reversal. In November, management offered a specific timeline for consolidated EBITDA breakeven within '1, 2 quarters'. This quarter, when asked directly, CFO Srinivas Koora declined, stating the company 'will not be able to disclose any future numbers'.
Both changes erode the reliability of management commentary. The Mihup discrepancy is not a rounding error; it is a fundamental change in a key portfolio metric. The guidance withdrawal is a shift from a company that was willing to quantify its path to profitability to one that now refuses to.
Operationally, Xelpmoc is a small entity. Q4 FY26 revenue was ₹10.8 million, up 52% year-on-year but essentially flat sequentially. The business has pivoted entirely to corporate clients, with products like DocXray and RelAI in early traction. Portfolio fair value rose to ₹726.8 million. The company is burning cash and has no timeline to stop.
The core question for investors is whether management's prior commentary was accurate, or whether this quarter's figures are. Without a reconciliation, the former is in doubt.
Two unexplained reversals in one quarter make management's future commentary harder to trust.